瘤微环境中的瘤细胞化介导的免疫逃避
Jeonghyun Kim1, Soyeon Park1, Jungseo Kim2
1Institute of Advanced Bio-Industry Convergence, Yonsei University, Seoul, Korea.
Experimental & molecular medicine
|December 31, 2024
概括
输血细胞症涉及免疫细胞之间的细胞膜转移,使抗原呈现和免疫调节成为可能. 这一过程,包括亡 (细胞死亡),影响瘤免疫力和免疫逃避机制.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 巨细胞症是一种细胞与细胞的相互作用,涉及血和细胞醇的交换.
- 与细胞分裂不同,细胞分裂保留了转移分子的表面局部.
- 例如包括从抗原呈现细胞转移到CD4 T细胞的MHCII类转移.
研究的目的:
- 为了探索免疫调节分子的细胞转移介导的转移.
- 为了阐明瘤微环境中的含义.
- 了解癌症的免疫逃避机制.
主要方法:
- 综述现有关于细胞瘤的文献.
- 在细胞与细胞相互作用期间分子转移的分析.
- 研究瘤中的免疫调节分子功能的研究.
主要成果:
- 巨细胞突变促进了带有抗原的MHCII类分子转移,产生"穿着"的CD4T细胞以呈现抗原.
- 受体细胞获得免疫调节分子 (例如CTLA-4,Tim3),调节抗瘤免疫力.
- 捐赠细胞经历了等离子体膜的损失,可能导致细胞亡 (细胞死亡).
结论:
- 输血细胞在免疫调节和抗原呈现中起着至关重要的作用.
- 免疫分子通过细胞转移会影响抗瘤免疫力.
- 了解输血细胞的机制是解读癌症免疫逃避的关键.
相关概念视频
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cytotoxic T Cells-mediated Immune Response
841
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
841
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


